Highlights

Prolor Biotech Downgraded by Summer Street (PBTH)

 Source: ABMN Staff   |   Publish date: Mon, 12 Nov 2012, 11:58 AM   |    >> Read article in News website

Prolor Biotech (NASDAQ: PBTH) was downgraded by research analysts at Summer Street from a “buy” rating to a “sell” rating in a report released on Monday.

Prolor Biotech traded down 3.16% on Monday, hitting $4.60. Prolor Biotech has a 52-week low of $3.11 and a 52-week high of $6.69. The company’s market cap is $291.7 million.

Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 29th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Jefferies Group initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 22nd. They set a “buy” rating and a $8.00 price target on the stock.

Prolor Biotech, Inc. (Prolor), formerly Modigene Inc. is a development-stage biopharmaceutical company, utilizing technology to develop versions of therapeutic proteins.

Share this

  Be the first to like this.
 


 

4633  2475  522  676 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 NVCN 2.816+1.396 
 BAC 22.091+0.251 
 AMD 9.441+0.761 
 CHK 7.705+0.225 
 SPY 221.485+0.485 
 XLF 23.065+0.145 
 PBR 10.86+0.41 
 VALE 8.74+0.08 
 NUGT 8.329-0.151 
 EEM 35.564+0.154 
Partners & Brokers